cdmoservices

[cdmoservices]

Aurigene offers state‑of‑the‑art GLP and non‑GLP bioanalytical services for drug discovery and development. Our high‑sensitivity LC‑MS/MS platforms support quantitative analysis of small molecules, therapeutic peptides, biomarkers, PROTACs, and complex molecules. With integrated DMPK, validated method development, rapid turnaround, and regulatory compliance support, accelerate your project from lead selection to IND/CTA.

[cdmoservices]

Aurigene Pharmaceutical Services offers a robust suite of pharmaceutical microbiology testing services, encompassing both in vitro and in vivo assays tailored to support anti-infective drug discovery and development. Operating within BSL-2 compliant laboratories and dedicated in vivo facilities, Aurigene's experienced scientific team collaborates closely with pharmaceutical innovators to advance antibacterial and antifungal agents.

[cdmoservices]

Aurigene Pharmaceutical Services, in strategic collaboration with Vipergen, offers advanced DNA Encoded Library (DEL) screening services designed to expedite hit identification and enhance drug discovery success rates. This integrated platform enables the screening of over a billion small-molecule compounds, either in living cells or with purified target proteins, providing a comprehensive approach to target engagement.

[cdmoservices]

​Aurigene Pharmaceutical Services offers comprehensive small molecule drug discovery services, providing both integrated and standalone solutions in chemistry and biology to innovator pharmaceutical companies. With over 20 years of experience, their team of highly qualified scientists operates from state-of-the-art facilities in Bangalore and Hyderabad, supporting clients through various pre-clinical discovery phases—from target identification to pre-clinical stage. Aurigene's offerings include medicinal chemistry, analytical chemistry, custom library synthesis, in vitro biology, ADME/DMPK services, in vivo pharmacology, and toxicology studies. Additionally, they leverage advanced technologies such as artificial intelligence-assisted drug discovery platforms and computer-aided drug design to accelerate the development of novel therapeutics. ​

[cdmoservices]

Aurigene Pharmaceutical Services offers specialized in vitro biology services, including standard and customized biochemical and cell-based assays, to support both standalone and integrated drug discovery programs. Their highly skilled team excels in assay development across various therapeutic areas and target classes, enhancing the progression of compounds toward clinical candidate nomination.

[cdmoservices]

Aurigene Pharmaceutical Services offers a wide range of standalone and integrated Computer-Aided Drug Design or CADD drug discovery CDMO services to facilitate candidate progression at every stage of drug discovery. Our holistic approach encompasses target identification, virtual screening, structure-based design, and compound optimization, supported by a team of highly skilled scientists and state-of-the-art tools. We routinely support discovery projects from target identification to clinical positioning of candidate compounds, with proven expertise in small molecule, PROTAC, and peptide drug discovery projects.

[cdmoservices]

Aurigene Discovery Technologies specializes in custom library synthesis services, offering tailored solutions for drug discovery and medicinal chemistry. Their services include designing diverse compound libraries to meet specific research goals, ensuring high-quality synthesis and scalability. With expertise in generating unique chemical libraries, Aurigene supports accelerated discovery efforts in pharmaceuticals and biotechnology.

[cdmoservices]

Aurigene Pharmaceutical Services offers comprehensive Early Phase Development and Pilot Facility services, designed to streamline the transition of small molecules from discovery to pre-clinical stages. Their state-of-the-art kilo labs in Hyderabad and Bangalore support the scale-up of compounds from gram-scale to multi-kilo scale, including process development and safety studies. Equipped with advanced analytical and process labs, the facilities enable rapid, phase-appropriate delivery of pre-clinical candidates, with specialized capabilities in peptides, oligonucleotides, and HPAPI development.